Tevogen Bio Holdings INC 10-Q quarterly reports

Tevogen Inc. filed its Q2 2026 Form 10-Q, detailing ongoing net losses, increased R&D spending, and efforts to regain Nasdaq listing compliance.

Tevogen Bio Holdings Inc. reported a net loss of $5.7 million for Q3 2025, while securing additional financing and facing a Nasdaq minimum bid price non-compliance notice.

Tevogen Bio Holdings Inc. reported continued net losses and negative cash flows for Q2 2025, pausing clinical trials until further funding is secured despite recent capital raises and commitments.

Tevogen Bio Holdings Inc. reports a net loss of $10.4 million for the first quarter of 2025, primarily due to operating expenses and non-cash stock-based compensation.

Tevogen Bio Holdings Inc. reported its financial results for the third quarter ended September 30, 2024, highlighting ongoing research and development efforts in T-cell therapy.

Tevogen Bio Holdings Inc. reported a net loss for the second quarter of 2024, alongside significant developments in financing and operational activities.

Tevogen Bio Holdings reported a net income of $11.3 million for Q1 2024, primarily due to a change in the fair value of convertible promissory notes, but faces substantial doubt about its ability to continue as a going concern.